Ophthaine

(Proparacaine)

PreclinicalSmall molecule

VVitae Pharmaceuticals Inc., an Allergan affiliate

Ophthaine is one of 43 small molecule programs targeting Bupivacaine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

BupivacaineCompleted

MPACompleted

Intravitreal InjectionsCompleted

BupivacainePreclinical

Completed

MPAPreclinical

Completed

Intravitreal InjectionsPreclinical

Completed

Competition

Competitive Landscape

52 competitors in MPA

#DrugCompanyPhaseTrials

Flomax

Sanofi

Approved

4 2

Repatha

Amgen

Approved

2 3

Myrbetriq

Astellas

Approved

1 4

Tremfya

Johnson & Johnson

Approved

1 5

Jardiance

Boehringer Ingelheim

Approved

2 6

Rituxan

Roche

Phase 3

3 7

Activella

Eli Lilly

Phase 3

2 8

Epsom Salt

FFresenius Kabi USA, LLC

Phase 3

3 9

Nitrostat

VViatris Specialty LLC

Phase 2

2 10

Obicetrapib

NNewAmsterdam Pharma

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Local Anesthetic1 trial

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

Completed·AAmerican Genomics, LLC·Phase 3·NCT05325853·61 enrolled

Pain Management1 trial

Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK)

Unknown status·—·Phase 4·NCT04283331·30 enrolled

Pilot Study1 trial

Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection

Completed·LLahey Clinic·N/A·NCT00769392·28 enrolled

Bupivacaine1 trial

Comparing Ropivacaine and Bupivacaine in DTFNB Anesthesia in Patients Undergoing Phacoemulsification

Completed·GGovernment Medical College, Haldwani·N/A·NCT02925832·100 enrolled

MPA1 trial

Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens

Completed·SSun Yat-sen University·N/A·NCT02609997·65 enrolled

2 more indications

Intravitreal Injections1 trial

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

Completed·MMayo Clinic·N/A·NCT02951351·36 enrolled

Unspecified1 trial

Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure

Unknown status·SSun Yat-sen University·N/A·NCT02613013·240 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

OPHTHAINE

NDA NDA008883

Jan 1, 1982

OPHTHETIC

NDA NDA012583

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Proparacaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Proparacaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Proparacaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA008883). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Vitae Pharmaceuticals Inc., an Allergan affiliate company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVitae Pharmaceuticals Inc., an Allergan affiliate

Ophthaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Local Anesthetic1 trial

Pain Management1 trial

Pilot Study1 trial

Bupivacaine1 trial

MPA1 trial

Intravitreal Injections1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News